BiotechTube

Filgotinib Maleate

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Jun 11, 2025 → Nov 30, 2027

NCT ID
NCT06964113

About Filgotinib Maleate

Filgotinib Maleate is a approved stage product being developed by Eisai for Ulcerative Colitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06964113. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

14 of 20 similar drugs in Ulcerative Colitis were approved

Approved (14) Terminated (5) Active (6)
✅Azathioprine + PlaceboCelltrionApproved
✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved
✅AdalimumabAbbVieApproved
✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved
✅GolimumabMerckApproved
✅GolimumabMerckApproved
✅Prefilled Syringe delivery of Golimumab + Smartject Device delivery of GolimumabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06964113ApprovedRecruiting
NCT06625242ApprovedActive

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
40
MirikizumabEli LillyPhase 2
35
Azathioprine + PlaceboCelltrionApproved
35
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
TacrolimusAstellas PharmaPhase 3
40
tacrolimus + PlaceboAstellas PharmaPhase 3
40
AJM300 + PlaceboEisaiPhase 3
40
GSK3050002 + PlaceboEisaiPhase 1
29
adalimumab + placeboEisaiPhase 3
40
E6007 + PlaceboEisaiPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 2
35
KHK4083 + PlaceboKyowa KirinPhase 1
29
Arm1 + Arm 2Zydus LifesciencesPhase 2
35
Mirikizumab + MirikizumabEli LillyPhase 3
44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 2
27
Mirikizumab + PlaceboEli LillyPhase 2
35
LY4268989 + PlaceboEli LillyPhase 2
42
Eltrekibart + Mirikizumab + PlaceboEli LillyPhase 2
42